成人mRNA COVID-19疫苗接种随机试验中特别关注严重不良事件
本研究为对辉瑞和莫德纳mRNA COVID-19疫苗安慰剂对照III期随机临床试验的二次分析,聚焦布莱顿协作特别关注不良事件。结果显示,两种疫苗合并的特别关注严重不良事件超额风险为每万接种者12.5例(95%CI 2.1至22.9),风险比1.43(95%CI 1.07至1.92)。辉瑞试验中疫苗组严重不良事件风险高36%,风险差每万接种者18.0例(95%CI 1.2至34.9)。
要点
- mRNA疫苗合并的特别关注严重不良事件超额风险为每万接种者12.5例(95%CI 2.1至22.9)。
- 辉瑞试验疫苗组严重不良事件风险高36%,风险比1.36(95%CI 1.02至1.83)。
- 莫德纳试验疫苗组严重不良事件风险高6%,风险比1.06(95%CI 0.84至1.33)。
核心结论
- 研究发现mRNA COVID-19疫苗特别关注严重不良事件的超额风险,提示需要进行正式的风险-获益分析,特别是按严重COVID-19结局风险分层的分析。
- 这些分析将需要公开参与者水平数据集。
研究设计与样本
- 对辉瑞和莫德纳mRNA COVID-19疫苗安慰剂对照III期随机临床试验(NCT04368728和NCT04470427)中报告的严重不良事件进行二次分析,聚焦布莱顿协作特别关注不良事件。
主要发现
- 辉瑞疫苗特别关注严重不良事件超额风险为每万接种者10.1例(95%CI -0.4至20.6),安慰剂基线为17.6。
- 莫德纳疫苗特别关注严重不良事件超额风险为每万接种者15.1例(95%CI -3.6至33.8),安慰剂基线为42.2。
- mRNA疫苗合并的特别关注严重不良事件超额风险为每万接种者12.5例(95%CI 2.1至22.9),风险比1.43(95%CI 1.07至1.92)。
- 辉瑞试验疫苗组严重不良事件风险高36%,风险差每万接种者18.0例(95%CI 1.2至34.9),风险比1.36(95%CI 1.02至1.83)。
- 莫德纳试验疫苗组严重不良事件风险高6%,风险差每万接种者7.1例(95%CI -23.2至37.4),风险比1.06(95%CI 0.84至1.33)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: In 2020, prior to COVID-19 vaccine rollout, the Brighton Collaboration created a priority list, endorsed by the World Health Organization, of potential adverse events relevant to COVID-19 vaccines. We adapted the Brighton Collaboration list to evaluate serious adverse events of special interest observed in mRNA COVID-19 vaccine trials. METHODS: Secondary analysis of serious adverse events reported in the placebo-controlled, phase III randomized clinical trials of Pfizer and Moderna mRNA COVID-19 vaccines in adults (NCT04368728 and NCT04470427), focusing analysis on Brighton Collaboration adverse events of special interest. RESULTS: Pfizer and Moderna mRNA COVID-19 vaccines were associated with an excess risk of serious adverse events of special interest of 10.1 and 15.1 per 10,000 vaccinated over placebo baselines of 17.6 and 42.2 (95 % CI -0.4 to 20.6 and -3.6 to 33.8), respectively. Combined, the mRNA vaccines were associated with an excess risk of serious adverse events of special interest of 12.5 per 10,000 vaccinated (95 % CI 2.1 to 22.9); risk ratio 1.43 (95 % CI 1.07 to 1.92). The Pfizer trial exhibited a 36 % higher risk of serious adverse events in the vaccine group; risk difference 18.0 per 10,000 vaccinated (95 % CI 1.2 to 34.9); risk ratio 1.36 (95 % CI 1.02 to 1.83). The Moderna trial exhibited a 6 % higher risk of serious adverse events in the vaccine group: risk difference 7.1 per 10,000 (95 % CI -23.2 to 37.4); risk ratio 1.06 (95 % CI 0.84 to 1.33). Combined, there was a 16 % higher risk of serious adverse events in mRNA vaccine recipients: risk difference 13.2 (95 % CI -3.2 to 29.6); risk ratio 1.16 (95 % CI 0.97 to 1.39). DISCUSSION: The excess risk of serious adverse events found in our study points to the need for formal harm-benefit analyses, particularly those that are stratified according to risk of serious COVID-19 outcomes. These analyses will require public release of participant level datasets.
引用
- Fraiman J, Erviti J, Jones M, et al. Serious adverse events of special interest following mRNA COVID-19 vaccination in randomized trials in adults. Vaccine. 2022. PMID: 36055877. doi:10.1016/j.vaccine.2022.08.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。